-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Basic Science

Program: General Sessions
Session: Ernest Beutler Lecture and Prize
Monday, December 11, 2023, 1:30 PM-2:30 PM

Takehisa Kitazawa, PhD, DVM

Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan; Chugai Pharmaceutical, Totsuka-Ku, SHZ, Japan

Disclosures: Kitazawa: Chugai Pharmaceutical Co., Ltd.: Current Employment, Current equity holder in publicly-traded company, Patents & Royalties: The inventor of several patents related to emicizumab. All rights of the patents have been assigned to Chugai Pharmaceutical Co., Ltd..

OffLabel Disclosure: My presentation will include the results of Phase 1 clinical study of emicizumab, a therapeutic antibody marketed in the US. The dosages used in the study are not identical to the dosages approved by FDA.

See more of: Ernest Beutler Lecture and Prize
See more of: General Sessions
Previous Presentation | Next Presentation >>